March 25, 2019
Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it received Human Research Ethics Committee (HREC) approval on March 20, 2019, for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The pilot study will evaluate the safety and effectiveness of NB1 in adult subjects with degenerative disc disease (DDD) at one level from L2-S1, who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion (TLIF).
July 23, 2018
Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $5.9 million funding; $3.9 million in equity and a $2 million credit facility.
March 29, 2018
Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $500,000 funding with Orthofix Holding, Inc.
December 20, 2017
Bone Biologics Corp. (OTC QB: BBLG), a developer of orthobiologic products for the spinal fusion, trauma and osteoporosis markets, today has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. In addition, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.
August 23, 2017
August 22, 2017
Bone Biologics (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of a $1.4 million funding round with Musculoskeletal Transplant Foundation and Hankey Capital, LLC.
August 03, 2017
Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company’s board of directors.
July 24, 2017
Bone Biologics Corporation (OTCQB: BBLG) announced today that it has commenced a private offering of up to $10,000,000 of its securities. The securities will initially only be offered to persons who are either stockholders of the company or who are “accredited investors,” as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).
July 06, 2016
Bone Biologics Corporation announced the engagement of Scott D. Boden, MD as Chief Medical Advisor. Dr. Boden is a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. He is also the Clinical Director of the Whitesides Orthopedic Research Laboratory.
June 14, 2016
Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the signing of an option agreement with UCLA, for an opportunity to exclusively license the use of the revolutionary bone growth factor Nell-1 in the treatment of osteoporosis.
February 29, 2016
Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the completion of a $5.75 million funding round with Musculoskeletal Transplant Foundation, OrthoFix Holdings, Inc. and Hankey Capital, LLC.
May 06, 2015
Zhang X, Carpenter D, Bokui N, Soo C, Miao S, Truong T, Wu B, Chen I, Vastardis H, Tanizawa K, Kuroda S and Ting K. J.Bone Miner.Res., 18(12):2126-2134, 2003.
High dose of NELL-1 can specifically induce apoptosis of osteoblasts, but not fibroblasts. This study shows that NELL-1 effects are more targeted to bone-forming cells (osteoblasts) than non-bone cells (fibroblasts). It also demonstrates that appropriate dosing of NELL-1 is important for optimal bone-forming effects.
Zhang X, Kuroda S, Carpenter D, Nishimura I, Soo C, Moats R, Lida K, Wisner E, Hu FY, Miao S, Beanes S, Dong C, Vastardis H, Longaker M, Tanizawa K, Kanayaman N,Saito N and Ting K. J.Clin.Invest., 110(6):861-870, 2002.
This publication studied the effects of NELL-1 in cells and in living mice. This study confirmed that NELL-1 promotes osteogenic, or bone-like, differentiation in cells. In addition, we made living mice that expressed NELL-1 in every cell of their body. Surprisingly, these mice were largely viable, and except for abnormal and excessive bone growth, did not manifest other major organ system abnormalities. This demonstrates potentially the safety of NELL-1.
Kuroda S, Oyasu M, Kawakami M, Kanayama N, Tanizawa K, Saito N, Abe T, Matsuhashi S, Ting K. BioChem BioPhy Res. Comm. 265:79-86 (1999).
NELL-1 and NELL-2 show distinct subcellular localization in cytoplasm, they both are partially secreted into the culture medium of COS-7 cells. NELL-1 mRNA is faintly expressed in adult neural cells, the NELL-2 mRNA is expressed abundantly. During mouse embryogenesis, expression of the NELL-2 mRNA is initiated 7–11 days postcoitum, simultaneously with neural plate formation. These results strongly suggest that the NELL-2 protein, similar to but not identical with TSP-1, is involved in the growth and differentiation of neural cells. Additionally, the NELL-1 and NELL-2 mRNAs were found to be expressed abundantly in Burkitt’s lymphoma Raji cells and colorectal adenocarcinoma SW480 cells, respectively. Thus, it is likely that the NELL proteins also participate in the growth, differentiation, and oncogenesis of cancer cell lines.